​

REGENXBIO (RGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RGNX Stock Forecast

REGENXBIO (RGNX) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $27.25, with a high of $39.00 and a low of $18.00. This represents a 223.25% increase from the last price of $8.43.

$5 $12 $19 $26 $33 $40 High: $39 Avg: $27.25 Low: $18 Last Closed Price: $8.43

RGNX Stock Rating

REGENXBIO stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

RGNX Price Target Upside V Benchmarks

TypeNameUpside
StockREGENXBIO223.25%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts129
Avg Price Target$30.00$26.00$32.89
Last Closing Price$8.43$8.43$8.43
Upside/Downside255.87%208.42%290.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2556---11
Jan, 2556---11
Dec, 24661--13
Nov, 24661--13
Oct, 24671--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2025Luca IssiRBC Capital$30.00$8.36258.85%255.87%
Nov 15, 2024Judah FrommerMorgan Stanley$22.00$11.1497.49%160.97%
Oct 10, 2024Danielle BrillRaymond James$18.00$9.1995.87%113.52%
Sep 05, 2024Yi ChenH.C. Wainwright$39.00$11.38242.71%362.63%
Jun 24, 2024Annabel SamimyStifel Nicolaus$40.00$12.79212.74%374.50%
Jun 07, 2024Paul ChoiGoldman Sachs$38.00$13.76176.16%350.77%
May 15, 2024Yi ChenH.C. Wainwright$38.00$15.80140.51%350.77%
Mar 11, 2024Yi ChenH.C. Wainwright$36.00$22.8557.55%327.05%
Mar 08, 2024Luca IssiRBC Capital$35.00$22.7553.85%315.18%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025RBC CapitalOutperformOutperformhold
Nov 18, 2024Raymond JamesOutperformOutperformhold
Oct 10, 2024Raymond JamesBuyBuyhold
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 05, 2024Goldman SachsUnderperformUnderperformhold
Aug 05, 2024H.C. WainwrightBuyBuyhold
Jun 20, 2024RBC CapitalOutperformOutperformhold
Jun 07, 2024H.C. WainwrightBuyBuyhold
Jun 07, 2024Goldman SachsBuyinitialise
May 15, 2024WedbushBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.98$3.01$-6.50$-6.02-----
Avg Forecast$-2.85$3.89$-6.19$-5.52$-4.72$-0.48$-2.20$-2.54$-0.33
High Forecast$-3.94$2.74$-8.95$-6.31$-4.79$-1.24$-4.65$-3.55$-0.49
Low Forecast$-2.01$5.38$-4.39$-2.61$-4.62$0.03$-0.56$-1.53$-0.24
Surprise %4.56%-22.62%5.01%9.06%-----

Revenue Forecast

$50M $210M $370M $530M $690M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$154.57M$470.35M$112.72M$90.24M-----
Avg Forecast$159.42M$492.16M$120.42M$118.32M$86.88M$321.48M$206.30M$391.55M$582.13M
High Forecast$123.01M$379.75M$93.43M$99.84M$79.03M$268.89M$200.38M$391.51M$466.03M
Low Forecast$206.22M$636.65M$161.77M$158.67M$89.69M$383.49M$212.22M$391.58M$800.54M
Surprise %-3.04%-4.43%-6.39%-23.73%-----

Net Income Forecast

$-350M $-230M $-110M $10M $130M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-111.25M$127.84M$-280.32M$-263.49M-----
Avg Forecast$-124.77M$170.21M$-155.31M$-263.49M$-205.87M$38.66K$-109.25M$-111.08M$-14.43M
High Forecast$-172.39M$119.67M$-186.37M$-316.19M$-209.49M$-54.20M$-203.32M$-155.06M$-21.47M
Low Forecast$-87.72M$235.18M$-124.25M$-210.80M$-202.25M$1.49M$-24.30M$-67.11M$-10.69M
Surprise %-10.83%-24.89%80.49%------

RGNX Forecast FAQ

Is REGENXBIO stock a buy?

REGENXBIO stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that REGENXBIO is a favorable investment for most analysts.

What is REGENXBIO's price target?

REGENXBIO's price target, set by 6 Wall Street analysts, averages $27.25 over the next 12 months. The price target range spans from $18 at the low end to $39 at the high end, suggesting a potential 223.25% change from the previous closing price of $8.43.

How does REGENXBIO stock forecast compare to its benchmarks?

REGENXBIO's stock forecast shows a 223.25% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for REGENXBIO over the past three months?

  • February 2025: 45.45% Strong Buy, 54.55% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 45.45% Strong Buy, 54.55% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 46.15% Strong Buy, 46.15% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is REGENXBIO’s EPS forecast?

REGENXBIO's average annual EPS forecast for its fiscal year ending in December is $-4.72 for 2024, a -21.59% decrease from the reported $-6.02 in 2023. The prediction for 2025 is $-0.48, $-2.2 for 2026, $-2.54 for 2027, and $-0.33 for 2028.

What is REGENXBIO’s revenue forecast?

REGENXBIO's average annual revenue forecast for its fiscal year ending in December is $86.88M for 2024, a -3.72% decrease from the reported $90.24M in 2023. The forecast for 2025 is $321.48M, $206.3M for 2026, $391.55M for 2027, and $582.14M for 2028.

What is REGENXBIO’s net income forecast?

For its fiscal year ending in December, REGENXBIO's average annual net income forecast is $-206M for 2024, reflecting a -21.87% decrease from the reported $-263M in 2023. The projection for 2025 is $38.66K, $-109M for 2026, $-111M for 2027, and $-14.432M for 2028.